0 XP   0   0   0

BAFNA PHARMACEUTICALS LTD.
Buy, Hold or Sell?

Should you buy, hold or sell BAFNA PHARMACEUTICALS LTD.?

I guess you are interested in BAFNA PHARMACEUTICALS LTD.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse BAFNA PHARMACEUTICALS LTD.

Let's start. I'm going to help you getting a better view of BAFNA PHARMACEUTICALS LTD.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is BAFNA PHARMACEUTICALS LTD. even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how BAFNA PHARMACEUTICALS LTD. is doing in the market. If the company is worth buying. The latest step is to find out how other investors value BAFNA PHARMACEUTICALS LTD.. The closing price on 2023-01-27 was INR101.00 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
BAFNA PHARMACEUTICALS LTD. Daily Candlestick Chart
BAFNA PHARMACEUTICALS LTD. Daily Candlestick Chart
Summary









1. Valuation of BAFNA PHARMACEUTICALS LTD.




Current price per share

INR101.00

2. Growth of BAFNA PHARMACEUTICALS LTD.




Is BAFNA PHARMACEUTICALS LTD. growing?

Current yearPrevious yearGrowGrow %
How rich?$7.7m$6.9m$751.4k9.7%

How much money is BAFNA PHARMACEUTICALS LTD. making?

Current yearPrevious yearGrowGrow %
Making money$633.5k$716.6k-$83k-13.1%
Net Profit Margin6.1%8.2%--

How much money comes from the company's main activities?

3. Financial Health of BAFNA PHARMACEUTICALS LTD.




Comparing to competitors in the industry




  Industry Rankings ()  



Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of BAFNA PHARMACEUTICALS LTD..

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit BAFNA PHARMACEUTICALS LTD. earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare BAFNA PHARMACEUTICALS LTD. to the  industry mean.
  • A Net Profit Margin of 6.1% means that ₹0.06 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BAFNA PHARMACEUTICALS LTD.:

  • The MRQ is 6.1%. The company is making a profit. +1
  • The TTM is 6.1%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ6.1%TTM6.1%0.0%
TTM6.1%YOY8.2%-2.1%
TTM6.1%5Y-21.9%+27.9%
5Y-21.9%10Y-21.9%0.0%
1.1.2. Return on Assets

Shows how efficient BAFNA PHARMACEUTICALS LTD. is using its assets to generate profit.

  • Above 5% is considered healthy but always compare BAFNA PHARMACEUTICALS LTD. to the  industry mean.
  • 5.7% Return on Assets means that BAFNA PHARMACEUTICALS LTD. generated ₹0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BAFNA PHARMACEUTICALS LTD.:

  • The MRQ is 5.7%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 5.7%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ5.7%TTM5.7%0.0%
TTM5.7%YOY6.7%-1.0%
TTM5.7%5Y-9.5%+15.2%
5Y-9.5%10Y-9.5%0.0%
1.1.3. Return on Equity

Shows how efficient BAFNA PHARMACEUTICALS LTD. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare BAFNA PHARMACEUTICALS LTD. to the  industry mean.
  • 8.2% Return on Equity means BAFNA PHARMACEUTICALS LTD. generated ₹0.08 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BAFNA PHARMACEUTICALS LTD.:

  • The MRQ is 8.2%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 8.2%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ8.2%TTM8.2%0.0%
TTM8.2%YOY10.3%-2.1%
TTM8.2%5Y-32.2%+40.4%
5Y-32.2%10Y-32.2%0.0%

1.2. Operating Efficiency of BAFNA PHARMACEUTICALS LTD..

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient BAFNA PHARMACEUTICALS LTD. is operating .

  • Measures how much profit BAFNA PHARMACEUTICALS LTD. makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare BAFNA PHARMACEUTICALS LTD. to the  industry mean.
  • An Operating Margin of 0.0% means the company generated ₹0.00  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BAFNA PHARMACEUTICALS LTD.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-10.6%+10.6%
5Y-10.6%10Y-10.6%0.0%
1.2.2. Operating Ratio

Measures how efficient BAFNA PHARMACEUTICALS LTD. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 1.53 means that the operating costs are ₹1.53 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of BAFNA PHARMACEUTICALS LTD.:

  • The MRQ is 1.527. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.527. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.527TTM1.5270.000
TTM1.527YOY1.552-0.025
TTM1.5275Y1.681-0.154
5Y1.68110Y1.6810.000

1.3. Liquidity of BAFNA PHARMACEUTICALS LTD..

1.3. Liquidity
1.3.1. Current Ratio

Measures if BAFNA PHARMACEUTICALS LTD. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 3.14 means the company has ₹3.14 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of BAFNA PHARMACEUTICALS LTD.:

  • The MRQ is 3.136. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.136. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.136TTM3.1360.000
TTM3.136YOY2.043+1.093
TTM3.1365Y1.994+1.142
5Y1.99410Y1.9940.000
1.3.2. Quick Ratio

Measures if BAFNA PHARMACEUTICALS LTD. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare BAFNA PHARMACEUTICALS LTD. to the  industry mean.
  • A Quick Ratio of 0.90 means the company can pay off ₹0.90 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BAFNA PHARMACEUTICALS LTD.:

  • The MRQ is 0.902. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.902. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.902TTM0.9020.000
TTM0.902YOY0.393+0.509
TTM0.9025Y0.622+0.280
5Y0.62210Y0.6220.000

1.4. Solvency of BAFNA PHARMACEUTICALS LTD..

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of BAFNA PHARMACEUTICALS LTD. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare BAFNA PHARMACEUTICALS LTD. to industry mean.
  • A Debt to Asset Ratio of 0.30 means that BAFNA PHARMACEUTICALS LTD. assets are financed with 30.3% credit (debt) and the remaining percentage (100% - 30.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BAFNA PHARMACEUTICALS LTD.:

  • The MRQ is 0.303. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.303. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.303TTM0.3030.000
TTM0.303YOY0.343-0.040
TTM0.3035Y0.443-0.140
5Y0.44310Y0.4430.000
1.4.2. Debt to Equity Ratio

Measures if BAFNA PHARMACEUTICALS LTD. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare BAFNA PHARMACEUTICALS LTD. to the  industry mean.
  • A Debt to Equity ratio of 43.5% means that company has ₹0.44 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BAFNA PHARMACEUTICALS LTD.:

  • The MRQ is 0.435. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.435. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.435TTM0.4350.000
TTM0.435YOY0.523-0.088
TTM0.4355Y1.658-1.223
5Y1.65810Y1.6580.000

2. Market Valuation of BAFNA PHARMACEUTICALS LTD.

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings BAFNA PHARMACEUTICALS LTD. generates.

  • Above 15 is considered overpriced but always compare BAFNA PHARMACEUTICALS LTD. to the  industry mean.
  • A PE ratio of 58.32 means the investor is paying ₹58.32 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BAFNA PHARMACEUTICALS LTD.:

  • The EOD is 46.384. Good. +1
  • The MRQ is 58.325. Good. +1
  • The TTM is 58.325. Good. +1
Trends
Current periodCompared to+/- 
EOD46.384MRQ58.325-11.940
MRQ58.325TTM58.3250.000
TTM58.325YOY55.744+2.581
TTM58.3255Y28.484+29.840
5Y28.48410Y28.4840.000
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of BAFNA PHARMACEUTICALS LTD..

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of BAFNA PHARMACEUTICALS LTD.:

  • The MRQ is 65.974. Seems overpriced? -1
  • The TTM is 65.974. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ65.974TTM65.9740.000
TTM65.974YOY11.899+54.075
TTM65.9745Y38.937+27.038
5Y38.93710Y38.9370.000

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of BAFNA PHARMACEUTICALS LTD. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of 4.78 means the investor is paying ₹4.78 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of BAFNA PHARMACEUTICALS LTD.:

  • The EOD is 3.800. Neutral. Compare to industry.
  • The MRQ is 4.778. Neutral. Compare to industry.
  • The TTM is 4.778. Neutral. Compare to industry.
Trends
Current periodCompared to+/- 
EOD3.800MRQ4.778-0.978
MRQ4.778TTM4.7780.000
TTM4.778YOY5.721-0.943
TTM4.7785Y2.659+2.119
5Y2.65910Y2.6590.000
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of BAFNA PHARMACEUTICALS LTD. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.5822.5820%2.357+10%6.645-61%6.645-61%
Book Value Growth--1.1081.1080%1.1090%1.644-33%1.644-33%
Book Value Per Share--26.58126.5810%23.998+11%20.047+33%20.047+33%
Book Value Per Share Growth--1.1081.1080%1.1090%1.644-33%1.644-33%
Current Ratio--3.1363.1360%2.043+53%1.994+57%1.994+57%
Debt To Asset Ratio--0.3030.3030%0.343-12%0.443-32%0.443-32%
Debt To Equity Ratio--0.4350.4350%0.523-17%1.658-74%1.658-74%
Dividend Per Share----0%-0%-0%-0%
Eps--2.1772.1770%2.463-12%-1.170+154%-1.170+154%
Eps Growth--0.8840.8840%4.685-81%2.784-68%2.784-68%
Free Cash Flow Per Share--0.2070.2070%-8.329+4115%-6.031+3008%-6.031+3008%
Free Cash Flow Per Share Growth--2.0252.0250%1.449+40%-3.794+287%-3.794+287%
Free Cash Flow To Equity Per Share--0.2070.2070%-8.329+4115%-6.719+3339%-6.719+3339%
Free Cash Flow To Equity Per Share Growth--2.0252.0250%1.307+55%1.182+71%1.182+71%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin--0.0610.0610%0.082-26%-0.219+462%-0.219+462%
Operating Margin----0%-0%-0.1060%-0.1060%
Operating Ratio--1.5271.5270%1.552-2%1.681-9%1.681-9%
Pb Ratio3.800-26%4.7784.7780%5.721-16%2.659+80%2.659+80%
Pe Ratio46.384-26%58.32558.3250%55.744+5%28.484+105%28.484+105%
Peg Ratio--65.97465.9740%11.899+454%38.937+69%38.937+69%
Price Per Share101.000-26%127.000127.0000%137.300-8%66.349+91%66.349+91%
Price To Total Gains Ratio39.110-26%49.17849.1780%58.253-16%35.856+37%35.856+37%
Profit Growth--0.8840.8840%2.236-60%1.270-30%1.270-30%
Quick Ratio--0.9020.9020%0.393+129%0.622+45%0.622+45%
Return On Assets--0.0570.0570%0.067-15%-0.095+267%-0.095+267%
Return On Equity--0.0820.0820%0.103-20%-0.322+493%-0.322+493%
Revenue Growth--1.1951.1950%1.677-29%1.284-7%1.284-7%
Total Gains Per Share--2.5822.5820%2.357+10%6.645-61%6.645-61%
Total Gains Per Share Growth--1.0961.0960%0.172+536%0.995+10%0.995+10%
Usd Book Value--7734276.9007734276.9000%6982845.300+11%5833241.175+33%5833241.175+33%
Usd Book Value Change Per Share--0.0320.0320%0.029+10%0.082-61%0.082-61%
Usd Book Value Per Share--0.3270.3270%0.295+11%0.247+33%0.247+33%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0270.0270%0.030-12%-0.014+154%-0.014+154%
Usd Free Cash Flow--60356.10060356.1000%-2423542.800+4115%-1754924.025+3008%-1754924.025+3008%
Usd Free Cash Flow Per Share--0.0030.0030%-0.102+4115%-0.074+3008%-0.074+3008%
Usd Free Cash Flow To Equity Per Share--0.0030.0030%-0.102+4115%-0.083+3339%-0.083+3339%
Usd Price Per Share1.242-26%1.5621.5620%1.689-8%0.816+91%0.816+91%
Usd Profit--633585.300633585.3000%716684.100-12%-1003123.425+258%-1003123.425+258%
Usd Revenue--10472269.20010472269.2000%8759801.700+20%7447333.275+41%7447333.275+41%
Usd Total Gains Per Share--0.0320.0320%0.029+10%0.082-61%0.082-61%
 EOD+3 -2MRQTTM+0 -0YOY+23 -155Y+25 -1310Y+25 -13

3.2. Fundamental Score

Let's check the fundamental score of BAFNA PHARMACEUTICALS LTD. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1546.384
Price to Book Ratio (EOD)Between0-13.800
Net Profit Margin (MRQ)Greater than00.061
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.902
Current Ratio (MRQ)Greater than13.136
Debt to Asset Ratio (MRQ)Less than10.303
Debt to Equity Ratio (MRQ)Less than10.435
Return on Equity (MRQ)Greater than0.150.082
Return on Assets (MRQ)Greater than0.050.057
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of BAFNA PHARMACEUTICALS LTD. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.310
Ma 20Greater thanMa 50101.015
Ma 50Greater thanMa 100100.669
Ma 100Greater thanMa 200102.157
OpenGreater thanClose97.100
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2022-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets902,444
Total Liabilities273,641
Total Stockholder Equity628,803
 As reported
Total Liabilities 273,641
Total Stockholder Equity+ 628,803
Total Assets = 902,444

Assets

Total Assets902,444
Total Current Assets513,988
Long-term Assets513,988
Total Current Assets
Cash And Cash Equivalents 194
Net Receivables 147,796
Inventory 202,805
Other Current Assets 161,658
Total Current Assets  (as reported)513,988
Total Current Assets  (calculated)512,453
+/- 1,535
Long-term Assets
Long-term Assets  (as reported)388,456
Long-term Assets  (calculated)0
+/- 388,456

Liabilities & Shareholders' Equity

Total Current Liabilities163,898
Long-term Liabilities109,743
Total Stockholder Equity628,803
Total Current Liabilities
Short Long Term Debt 11,508
Accounts payable 124,049
Other Current Liabilities 21,491
Total Current Liabilities  (as reported)163,898
Total Current Liabilities  (calculated)157,048
+/- 6,850
Long-term Liabilities
Long term Debt 78,920
Long-term Liabilities Other 10,656
Long-term Liabilities  (as reported)109,743
Long-term Liabilities  (calculated)89,576
+/- 20,167
Total Stockholder Equity
Total Stockholder Equity (as reported)628,803
Total Stockholder Equity (calculated)0
+/- 628,803
Other
Capital Stock236,563
Common Stock Shares Outstanding 23,656
Net Debt 90,234
Net Invested Capital 719,231
Net Working Capital 350,090



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
> Total Assets 
0
0
1,194,721
713,126
864,659
902,444
902,444864,659713,1261,194,72100
   > Total Current Assets 
771,844
487,391
484,690
360,957
496,682
513,988
513,988496,682360,957484,690487,391771,844
       Cash And Cash Equivalents 
0
0
1,395
81,853
7,476
194
1947,47681,8531,39500
       Net Receivables 
565,449
286,660
305,979
130,150
95,595
147,796
147,79695,595130,150305,979286,660565,449
       Inventory 
167,399
106,742
92,823
114,116
154,434
202,805
202,805154,434114,11692,823106,742167,399
       Other Current Assets 
11,691
64,389
57,961
30,604
228,616
161,658
161,658228,61630,60457,96164,38911,691
   > Long-term Assets 
0
0
710,031
352,169
367,977
388,456
388,456367,977352,169710,03100
       Property Plant Equipment 
485,750
448,604
370,190
351,812
0
0
00351,812370,190448,604485,750
       Goodwill 
0
0
358
358
0
0
0035835800
       Long-term Assets Other 
0
0
9,950
-2
-2
-3
-3-2-29,95000
> Total Liabilities 
0
0
1,006,200
201,172
296,948
273,641
273,641296,948201,1721,006,20000
   > Total Current Liabilities 
814,717
598,468
708,209
170,996
243,087
163,898
163,898243,087170,996708,209598,468814,717
       Short Long Term Debt 
0
0
232,397
0
105,000
11,508
11,508105,0000232,39700
       Accounts payable 
239,043
286,102
395,585
125,414
106,916
124,049
124,049106,916125,414395,585286,102239,043
       Other Current Liabilities 
116,578
46,357
33,986
27,183
21,497
21,491
21,49121,49727,18333,98646,357116,578
   > Long-term Liabilities 
0
0
297,991
30,176
53,861
109,743
109,74353,86130,176297,99100
       Long-term Liabilities Other 
0
0
6,322
0
1
10,656
10,656106,32200
       Deferred Long Term Liability 
5,782
5,316
9,950
0
0
0
0009,9505,3165,782
> Total Stockholder Equity
0
0
190,582
511,147
567,711
628,803
628,803567,711511,147190,58200
   Common Stock
186,563
236,563
236,563
23,656
0
0
0023,656236,563236,563186,563
   Retained Earnings -660,155-711,666-763,295-516,002-327,297-159,932
   Accumulated Other Comprehensive Income 000000
   Capital Surplus 000000
   Treasury Stock000000



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2022-03-31)

Gross Profit (+$)
totalRevenue851,404
Cost of Revenue-512,858
Gross Profit338,546338,546
 
Operating Income (+$)
Gross Profit338,546
Operating Expense-787,055
Operating Income64,349-448,509
 
Operating Expense (+$)
Research Development-
Selling General Administrative39,234
Selling And Marketing Expenses-
Operating Expense787,05539,234
 
Net Interest Income (+$)
Interest Income446
Interest Expense-5,242
Net Interest Income-7,492-4,796
 
Pretax Income (+$)
Operating Income64,349
Net Interest Income-7,492
Other Non-Operating Income Expenses-
Income Before Tax (EBT)73,07664,349
EBIT - interestExpense = -5,242
51,511
56,753
Interest Expense5,242
Earnings Before Interest and Taxes (ebit)-78,318
Earnings Before Interest and Taxes (ebitda)133,251
 
After tax Income (+$)
Income Before Tax73,076
Tax Provision-0
Net Income From Continuing Ops73,07673,076
Net Income51,511
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-7,492
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
NGU24-NYM.COMM
3 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGU24-NYM.COMM.

NGU24-NYM.COMM Daily Candlestick Chart
NGM24-NYM.COMM
3 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGM24-NYM.COMM.

NGM24-NYM.COMM Daily Candlestick Chart
NGQ24-NYM.COMM
3 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGQ24-NYM.COMM.

NGQ24-NYM.COMM Daily Candlestick Chart
ISKJ.MCX
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ISKJ.MCX.

ISKJ.MCX Daily Candlestick Chart
CHKZ.MCX
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CHKZ.MCX.

CHKZ.MCX Daily Candlestick Chart
VSYD.MCX
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VSYD.MCX.

VSYD.MCX Daily Candlestick Chart
VRSB.MCX
3 hours ago

I found you a Golden Cross on the daily chart of VRSB.MCX.

VRSB.MCX Daily Candlestick Chart
TBRU.MCX
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TBRU.MCX.

TBRU.MCX Daily Candlestick Chart
SNGSP.MCX
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SNGSP.MCX.

SNGSP.MCX Daily Candlestick Chart
RBCM.MCX
3 hours ago

I found you a Golden Cross on the daily chart of RBCM.MCX.

RBCM.MCX Daily Candlestick Chart
OKEY.MCX
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of OKEY.MCX.

OKEY.MCX Daily Candlestick Chart
MTLR.MCX
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MTLR.MCX.

MTLR.MCX Daily Candlestick Chart
MRKZ.MCX
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MRKZ.MCX.

MRKZ.MCX Daily Candlestick Chart
KRKN.MCX
3 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of KRKN.MCX.

KRKN.MCX Daily Candlestick Chart
JNOS.MCX
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JNOS.MCX.

JNOS.MCX Daily Candlestick Chart
BLNG.MCX
3 hours ago

I found you a Golden Cross on the daily chart of BLNG.MCX.

BLNG.MCX Daily Candlestick Chart
ASSB.MCX
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ASSB.MCX.

ASSB.MCX Daily Candlestick Chart
CSYZ.MU
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CSYZ.MU.

CSYZ.MU Daily Candlestick Chart
MOH.MU
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MOH.MU.

MOH.MU Daily Candlestick Chart
TBK.V
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TBK.V.

TBK.V Daily Candlestick Chart
UMDK.F
3 hours ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of UMDK.F.

UMDK.F Daily Candlestick Chart
RY4C.BE
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of RY4C.BE.

RY4C.BE Daily Candlestick Chart
PLY.BE
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of PLY.BE.

PLY.BE Daily Candlestick Chart
PDL.LSE
3 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of PDL.LSE.

PDL.LSE Daily Candlestick Chart
27F0.MU
3 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of 27F0.MU.

27F0.MU Daily Candlestick Chart